Despite advances, the roles of genetics and microenvironment in CLL are not fully understood, and curative treatments may ...

The most common TRAEs of any grade were acneiform rash (93%), diarrhea (89%), proteinuria (78%), and dry skin (64%).

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

A UK biotech firm spent years gathering genetic data that has uncovered 1 million previously unknown microbial species and ...

New data support tailoring regional nodal irradiation in patients treated with neoadjuvant chemotherapy on the basis of their ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

The initial report of monotherapy with the BCL-2 inhibitor venetoclax showed it had durable clinical activity and favorable ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III ...

Other appointments to BIO's board for the 2025 through 2026 term include: Arcutis Bio's Frank Watanabe, named vice-chair; ...

In this interview with TRUST-I and TRUST-II trial investigator, Jorge J. Nieva, MD, USC Keck School of Medicine, he walks through the design of the trials, the results that supported the FDA approval, ...

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.